Previous 10 | Next 10 |
- New Positive Phase 2 Results in Metastatic Triple Negative Breast Cancer (mTNBC) Indicate That Use of Trilaciclib in Combination with a TROP2 ADC May Be Associated with Improved Median OS Compared to Historical Data for the ADC Alone - - Exploratory Analysis of a More Comparable Patient P...
RESEARCH TRIANGLE PARK, N.C., May 23, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that mature Phase 2 results describing the positive impact of trilaciclib administered in combination with the TROP2 antibody-drug conjuga...
RESEARCH TRIANGLE PARK, N.C., May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1’s Chief Medical Officer Dr. Raj Malik and Chief Commercial Officer Andrew Perry will participate in a fireside chat at TD Cowen&...
RESEARCH TRIANGLE PARK, N.C. and SAN FRANCISCO, May 22, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, and Deimos Biosciences, a portfolio company of Jupiter Bioventures, announced a global licensing agreement (excluding the Asia-Pacific r...
2024-05-09 10:16:00 ET More on G1 Therapeutics G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Call Transcript Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeu...
2024-05-01 12:04:08 ET G1 Therapeutics, Inc. (GTHX) Q1 2024 Earnings Conference Call May 01, 2024 08:30 AM ET Company Participants Will Roberts - Investor Relations Jack Bailey - Chief Executive Officer Andrew Perry - Chief Commercial Officer Raj Malik - Chie...
2024-05-01 08:30:54 ET More on G1 Therapeutics Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics, Inc. (GTHX) Q4 2023 Earnings Call Transcript G1 Therapeutics reports mixed Q1 results; reaffirms FY24 outlook G1 Thera...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
2024-05-01 06:35:23 ET More on G1 Therapeutics Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape G1 Therapeutics GAAP EPS of -$0.21 beats by $0.07, revenue of $14.9M beats by $1.87M Seeking Alpha’s Quant Rating on G1 Therapeutics ...
- Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 - - Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million - - Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibod...
News, Short Squeeze, Breakout and More Instantly...
RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that the Company has been added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes as of...
2024-06-25 08:00:05 ET Edward White from H.C. Wainwright issued a price target of $3.00 for GTHX on 2024-06-25 06:22:00. The adjusted price target was set to $3.00. At the time of the announcement, GTHX was trading at $2.22. GTHX currently trades -63.60% versus its 52 we...
A look at the top 10 most actives in the United States Agrify Corporation (AGFY) rose 164.2% to $0.6658 on volume of 125,460,313 shares NVIDIA Corporation (NVDA) fell 2.9% to $122.88 on volume of 51,163,891 shares Crown Electrokinetics Corp. (CRKN) fell 0.3% to $0.04097 on volume of 44,45...